Over 26 million people worldwide may be struggling with opioid use disorder. Over a 17-year period, opioid deaths in Canada increased by 592%. Over a 1-year period, opioids accounted for 63% of all drug overdose deaths, which increased by 30.8% over the same time period.
AphioTx is a clinical-stage biotechnology company developing a platform of small molecule and protein-based biotherapeutics targeting opioid withdrawal symptoms. Phase 2 clinical trials are planned to begin in 2022.
The healthcare analytics market is rapidly growing at a rate of 27% CAGR. There are over 5,000 pharmaceutical companies worldwide that need better data platforms, and over 18,000 patient organizations in the US alone trying to advance research in their disease areas.
Lumiio specializes in real-world data collection services that drive health outcomes. Lumiio connects stakeholders in health communities by aligning interests, and working towards the common goal of improving solutions for diagnostics, treatment, and care.
Modelis is a patient-centric biotechnology company that expedites drug discovery in the rare genetic disease space. The process involves AI-integrated screening of publicly and privately available pharmaceutical molecules with world-class scientific rigor in small animal models.
Rare genetic diseases such as Duchenne Muscular Dystrophy effect 1 in every 3,500 male births with no treatment available, with increased risk of cardiac failure as patients age. Muscular dystrophies are known to cause 1 in every 2,500 deaths in the United States, usually due to cardiac or respiratory muscle failure.
OligomicsTx is a preclinical biotechnology company combining innovative delivery mechanisms with their ground-breaking novel genetic therapies for rare diseases like Duchenne Muscular Dystrophy.
Raft Digital Therapeutics is building a virtual physiotherapy platform to enable unsupervised, at-home rehabilitation programs starting with people with Spinal Muscular Atrophy (SMA) with a large pharma partner and then expanding to other diseases. Using interactive gaming, the company is working to make these important programs more affordable, accessible, and fun.
AazeinTx’s novel treatment is ready for phase 2 asthma trials, demonstrating the potential to impact over 300 million people worldwide. Preclinical read-outs are ready to launch for chronic obstructive pulmonary disease (COPD), chemotherapy-induced pain, and vulvodynia.
AazeinTx is the global leader in next generation TRPV1 modulation, targeting five distinct neuroinflammatory diseases with a novel peripherally acting TRPV1 immuno-modulator. This next generation molecule has a robust safety profile, and has already been tested in over 118 humans.
Taylored Biotherapeutics is a world-class microbiome research company focused on mental health and developmental disorders, and is poised to create a new class in this space. There have been limited developments for approximately twenty-five years within this niche area of research.
Rapid Infection Diagnostics has designed a series of fully-automated diagnostic devices that will take blood and urine samples to provide identification and susceptibility testing of bacteria in approximately 25% of the time of current tests (with similarly high levels of accuracy).
Pure Life Carbon is a clean-tech growing medium company utilizing advanced carbon technology to materially increase crop yields, ensure crop consistency, while reducing greenhouse gas emissions and agricultural waste.
Myera is an Indigenous owned company that has established an arctic char fish farm and is investing in leading edge technology. Myera’s goal is to become a world leader in land based sustainable fish farming and related agricultural solutions.